Head & Neck Cancer

The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.

Patients with oropharyngeal cancer demonstrate higher rates of ever performing, timing, number of partners and intensity in oral sex than matching participants, suggesting an association between behavior and diagnosis.

Legendary Van Halen lead guitarist, Eddie Van Halen, died on Tuesday from cancer. He was 65.

For head and neck cancer survivor Jason Mendelsohn surviving cancer was only the beginning of his journey as handling severe side effects from treatment altered his day-to-day life.

From the death of civil rights icon John Lewis to a woman pretending to have cancer as part of a larger donation scam, here’s what’s making the headlines in the cancer space this week.

A laryngectomy choir offers rehabilitation and inspiration to patients after throat cancer.

The Food and Drug Administration (FDA) has granted accelerated approval to expand the indication of Gardasil 9 (Human papillomavirus 9-valent vaccine, recombinant), a vaccine for the prevention of HPV, to prevent oropharyngeal and other head and neck cancers caused by certain HPV types.

Voice actor Rob Paulsen opens up about how a lump on his neck led to a stage 3 diagnosis.

Patients with head and neck paragangliomas, a rare neuroendocrine tumor type, may be safely and effectively treated with proton therapy.

Marijuana is often linked to fighting cancer and its effects, but in the case of head and neck squamous cell carcinoma, researchers found that it may increase the progression of the disease.

Mona P is finding hope, life and healing after carcinoma of the pharynx.

Fast track designation has been granted for the investigational therapy tipifarnib to treat patients with HRAS mutant head and neck squamous cell carcinomas.

Patients with head and neck cancer who received acupuncture during therapy saw lower incidence and severity of dry mouth compared with those who received oral health education.

The investigational agent tipifarnib shows promise in patients with head and neck cancer who have a certain gene mutation.

Poison’s Rikki Rockett discusses the immunotherapy clinical trial that led him into remission.

The Food and Drug Administration has approved Keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in certain patients.

From Beth Chapman’s untimely passing to cancer fundraising via esports, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

Patients with head and neck cancer may soon have more effective, less toxic choices as immunotherapy moves into first-line treatment and novel targeted drugs are explored.

Compared with the general population, men and women with type 2 diabetes face greater risk of developing certain cancers, such as colorectal, kidney, liver and more.

This essay was written by Maria Campos nominating Mary Kernan, RN, OCN, of Smilow Cancer Center At Yale New Haven Health, New Haven, Connecticut, for CURE®'s Extraordinary Healer® Award.

Here are the top 5 CURE stories for April 2019.

Use of two medicated mouthwashes reduced pain from oral mucositis during the first four hours after administration; however, the results were not deemed clinically different when compared with placebo.

From artificial intelligence to a surprise FDA resignation, check out this week’s quick overview of what is making headlines in the cancer space.

A five-year lesson in cancer, worry and hope.

The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.